Valbiotis announced on Friday the successful completion of its €15 million capital increase, aimed at accelerating the commercialization of its food supplements offering.

In a press release, the La Rochelle-based group points out that the operation was already secured by guarantee commitments for a total amount of €11.6 million.

Subscription demand amounted to 7.9 million euros, of which 3.9 million euros came from existing shareholders, 3.5 million from the global placement and 500,000 euros from the public offering.

The aim of this fund-raising is to ensure the company's expansion and enable it to self-finance its growth, while maintaining its focus on 100% plant-based dietary supplements.

The group intends in particular to prepare for the marketing of Totum.63 (pre-diabetes management) alongside Nestlé Health Science, and initiate direct marketing of other products in France, including Totum.070 (cholesterol reduction).

On the stock market, the share has gained over 31% this year.

Copyright (c) 2023 CercleFinance.com. All rights reserved.